drugset
Drugs / BEZETABART DEBOTANSINE
last change Mar 2024 re-read 3 minutes ago

BEZETABART DEBOTANSINE

also known as Bezetabart debotansina · SP7675 · STRO-001

targets CD74

Developed for
diffuse large B-cell lymphoma · follicular lymphoma · mantle cell lymphoma · plasma cell myeloma
Investigated by
Sutro Biopharma, Inc.

Trials 1

today NCT03424603 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03424603 Feb 2018 → Feb 2024 diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, plasma cell myeloma Sutro Biopharma, Inc. Completed No outcome recorded

Press releases naming this drug 11 releases

DateIssuerRelease
2021-10-12 Sutro Biopharma, Inc. Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China sutrobio.com ↗
2020-12-07 Sutro Biopharma, Inc. Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting sutrobio.com ↗
2020-11-04 Sutro Biopharma, Inc. American Society of Hematology Conference 2020 – STRO-001 – Abstract sutrobio.com ↗
2019-11-06 Sutro Biopharma, Inc. American Society of Hematology Conference 2019 – STRO-001 – Abstract sutrobio.com ↗
2019-07-15 Sutro Biopharma, Inc. International Conference in Malignant Lymphoma (ICML) 2019 – STRO-001 Poster sutrobio.com ↗
2019-06-15 Sutro Biopharma, Inc. Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress sutrobio.com ↗
2019-06-15 Sutro Biopharma, Inc. European Hematology Association Congress (EHA) 2019 – STRO-001 Poster sutrobio.com ↗
2019-05-16 Sutro Biopharma, Inc. European Hematology Association (EHA) 2019 – STRO-001 Abstract sutrobio.com ↗
2019-04-11 Sutro Biopharma, Inc. American Association for Cancer Research (AACR) 2019 – STRO-001 Poster sutrobio.com ↗
2018-10-12 Sutro Biopharma, Inc. Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma sutrobio.com ↗
2018-01-01 Sutro Biopharma, Inc. STRO-001 – Publication Highlights sutrobio.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BEZETABART DEBOTANSINE ChEMBL registry synonym — accepted as the source's own label CHEMBL5314812 ↗
Known as Bezetabart debotansina ChEMBL registry synonym — accepted as the source's own label CHEMBL5314812 ↗
Known as SP7675 ChEMBL registry synonym — accepted as the source's own label CHEMBL5314812 ↗
Known as STRO-001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03424603 ↗
Route Intravenous “STRO-001 will be dosed as an intravenous (IV) infusion on Day 1 of a 21-day cycle” NCT03424603 ↗
Target CD74 “Anti-CD74 Antibody Drug Conjugate” NCT03424603 ↗